APPENDIX 4D

Consolidated Interim Financial Report for the half-year ended 31 December 2018

1. Name	of Entity
---------	-----------

Clearvue Technologies Limited (ABN 45 071 397 487)	
Reporting Period	Half-year ended 31 December 2018

Half-year ended 31 December 2017

2. Results for Announcement to Market

Previous Corresponding Reporting Period

Financial results	Up / Dov	vn % Change	2018	2017	
Revenue from ordinary activities	Up	257%	727,997	463,064	
Loss after tax from ordinary activities attributable to members	Up	495%	(2,667,754)	(448,560)	
Loss attributable to members	Up	495%	(2,667,754)	(448,560)	
Final and interim dividends		It is not proposed that either a final or interim			
		dividend be paid.			
Record date for determining entitlements to the dividend N/A					
Brief explanation of any of the figures reported above		During the period, the Company entered into a few different Memorandums to further the development and distribution the Clearvue products in Australia and Europe.			

3. Net Tangible Asset Backing per Ordinary Share	Cents
Net tangible asset backing per ordinary share – current reporting period	2.99
Net tangible asset backing per ordinary share – previous reporting period	0.26

4. Control Gained Over Entities

Details of entities over which control has been gained or lost	N/A	

5. Dividends Paid and Payable

Details of dividends or distribution payments	No dividends or distributions are
Details of dividends of distribution payments	payable.

6. Dividend Reinvestment Plans

	Technologies Limited.
·	
Details of dividend or distribution reinvestment plans	program in operation for Clearvue
	rnere is no dividend reinvestment

7. Details of Associates	
Details of associates and joint venture entities	N/A
8. Foreign Entities	
Foreign entities to disclose which accounting standards are used in compiling the report	N/A.
9. Review Opinion	
Details of any audit dispute or qualification	There are no audit disputes or qualifications to the review opinion.

Victor Rosenberg Chairman

Perth WA,

Date: 28 February 2019





CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES

ABN 45 071 397 487

Consolidated Interim Financial Report

For the half-year ended 31 December 2018

COMPANY INFORMATION

DIRECTORS

Victor Rosenberg, Executive Chairman Jamie Lyford, Executive Director Sean Rosenberg, Non-executive Director Ivan Wu, Non-executive Director Stuart Carmichael, Non-executive Director

COMPANY SECRETARY

Brett Tucker
Deborah Ho (appointed 31 January 2019)

REGISTERED OFFICE

Ground Floor 16 Ord Street West Perth WA 6005

PRINCIPAL BANKERS

National Australia Bank Limited

AUDITORS

Grant Thornton Audit Pty Ltd Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000

SOLICITORS

Steinepreis Paganin 16 Milligan Street Perth WA 6000

SHARE REGISTRY

Registry Direct PO Box 18366 Collins Street East Melbourne VIC 8003

STOCK EXCHANGE LISTING

Shares are listed on the Australian Securities Exchange (ASX code: CPV)

DIRECTORS' REPORT

Index	
	<u>PAGE</u>
Directors' Report	1 – 2
Auditor's Independence Declaration	3
Consolidated Statement of Profit or Loss and Other Comprehensive Income	4
Consolidated Statement of Financial Position	5
Consolidated Statement of Changes in Equity	6
Consolidated Statement of Cash Flows	7
Notes to the Financial Statements	8 – 15
Directors' Declaration	16
Independent Auditor's Report	17 – 18

DIRECTORS' REPORT

The Directors are pleased to present their report together with the consolidated financial statements of Clearvue Technologies Limited ("the Company") and its controlled entities ("the Group") at the end of, or during, the half-year ended 31 December 2018.

1. DIRECTORS

The name of the Directors in office at any time during or since the end of the half-year are:

Victor Rosenberg Sean Rosenberg Jamie Lyford Ivan Wu Stuart Carmichael

2. PRINCIPAL ACTIVITIES

The principal activities of the Group during the course of the half-year were research and development activities applied to the Company's world leading solar glass technology.

3. REVIEW OF OPERATIONS AND FINANCIAL RESULTS

The operating result of the Group for the current half-year is a loss of \$2,667,754 (2017 restated: \$448,560).

The Company has entered into a few different Memorandums during the half-year to further the development and distribution the Clearvue products in Australia and Europe.

4. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

There were no significant changes in the state of affairs of the Group during the financial half-year.

5. EVENTS ARISING SINCE THE END OF THE REPORTING PERIOD

On 31 January 2019, Ms Deborah Ho was appointed as joint company secretary.

On 1 February 2019, 350,000 fully paid ordinary shares were issued at nil consideration to an employee pursuant to the Company's Employee Share Plan.

On 27 February 2019, the Company executed a Distribution Licence Agreement with Grafsol General Trading LLC.

No other matters or circumstances not otherwise dealt with in this report have arisen since the end of the financial year to the date of this report which has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or state of affairs of the Group in subsequent financial years.

DIRECTORS' REPORT

6. AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 has been included on page 3.


Signed in accordance with a resolution of the Board of Directors.

Victor Rosenberg

Chairman

Perth WA,

Date: 28 February 2019



Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000

Correspondence to: PO Box 7757 Cloisters Square Perth WA 6850

T +61 8 9480 2000 F +61 8 9322 7787 E info.wa@au.gt.com W www.grantthornton.com.au

Auditor's Independence Declaration

To the Directors of ClearVue Technologies Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of ClearVue Technologies Limited for the half-year ended 31 December 2018. I declare that, to the best of my knowledge and belief, there have been:

- a No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b No contraventions of any applicable code of professional conduct in relation to the review.

GRANT THORNTON AUDIT PTY LTD

Chartered Accountants

L A Stella

Partner - Audit & Assurance

Perth, 28 February 2019

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	<u>Note</u>	Consolidated 31 Dec 2018 \$	Consolidated 31 Dec 2017 Restated \$
Revenue		36,695	56,345
Other income	5	691,302	406,719
		727,997	463,064
Expenses Administrative expense	6	(3,083,492)	(500,590)
Depreciation and amortisation expense	U	(44,413)	(28,355)
Finance costs		(3,158)	(8,573)
Project costs		(264,688)	(374,106)
.,		(3,395,751)	(911,624)
Loss before income tax		(2,667,754)	(448,560)
Income tax expense		-	-
Loss for the year, representing total comprehensive loss for the half-year		(2,667,754)	(448,560)
Loss per share for loss attributable to the owners of the Company (cents)			
Basic loss per share		(2.77)	(1.59)
Diluted loss per share		(2.77)	(1.59)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2018

	<u>Note</u>	Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 Restated \$
<u>ASSETS</u>			
Current Assets			
Cash and cash equivalents	7	2,912,634	3,818,763
Other receivables	8	334,333	118,588
		3,246,967	3,937,351
Non-Current Assets			
Plant and equipment	9	140,658	108,376
Intangible assets	10	1,617,823	1,493,159
		1,758,481	1,601,535
Total Assets		5,005,448	5,538,886
<u>LIABILITIES</u> Current Liabilities			
Trade and other payables	11	410,171	316,952
Provisions	12	65,600	-
		475,771	316,952
Non-Current Liabilities			
Provisions	12	5,005	-
		5,005	-
Total Liabilities		480,776	316,952
Net Assets		4,524,672	5,221,934
EQUITY			
Share capital	13	10,583,302	9,993,302
Share-based payments reserve	14	4,223,027	2,842,535
Retained earnings		(10,281,657)	(7,613,903)
Total Equity		4,524,672	5,221,934

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	Share Capital	Share Application Monies	Share- Based Payments Reserve	Retained Earnings	Total
	<u> </u>	\$	\$	\$	\$
Balance at 1 July 2017	4,880,646	98,000	536,900	(3,928,073)	1,587,473
Issue of ordinary shares	626,000	(98,000)	-	-	528,000
Share issue costs	(99,659)	-	-	-	(99,659)
Loss after income tax expense for the year	-	-	-	(673,624)	(673,624)
Other comprehensive income for the year	-	-	-	-	-
Total comprehensive loss for the year	-	-	-	(673,624)	(673,624)
Balance at 31 December 2017	5,406,987	-	536,900	(4,601,697)	1,342,190
Prior period adjustment (Note 4)	-	-	-	225,064	225,064
Balance at 31 December 2017 – Restated	5,406,987	-	536,900	(4,376,633)	1,567,254
Balance at 1 July 2018	9,993,302	-	2,842,535	(7,369,663)	5,466,174
Prior period adjustment (Note 4)	-	-	-	(244,240)	(244,240)
Balance at 1 July 2018 – Restated	9,993,302	-	2,842,535	(7,613,903)	5,221,934
Options exercised	590,000	-	-	-	590,000
Share-based payments	-	-	1,380,492	-	1,380,492
Loss after income tax expense for the year	-	-	-	(2,667,754)	(2,667,754)
Other comprehensive income for the year	-	-	-	-	-
Total comprehensive loss for the year	-	-	-	(2,667,754)	(2,667,754)
Balance at 31 December 2018	10,583,302	-	4,223,027	(10,281,657)	4,524,672

CLEARVUE TECHNOLOGIES LIMITED ABN 45 071 397 487

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

Cash flows from operating activities (2,667,754) (448,560) Loss before income tax (2,667,754) (448,560) Adjustment for: 29,416 23,115 Research and development net income (455,201) (225,064) Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables (26,185) 7,482 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost <td< th=""><th></th><th>Consolidated 31 Dec 2018</th><th>Consolidated 31 Dec 2017 Restated</th></td<>		Consolidated 31 Dec 2018	Consolidated 31 Dec 2017 Restated
Loss before income tax	Cash flows from operating activities	Þ	\$
Adjustment for: Depreciation of plant and equipment 14,997 5,240 Amortisation of intangible assets 29,416 23,115 Research and development net income (455,201) (225,064) Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables 26,711 101,437 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000	. •	(2 667 754)	(448 560)
Depreciation of plant and equipment 14,997 5,240 Amortisation of intangible assets 29,416 23,115 Research and development net income (455,201) (225,064) Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables 26,711 101,437 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 3130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activit		(2,001,101)	(110,000)
Amortisation of intangible assets 29,416 23,115 Research and development net income (455,201) (225,064) Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables (26,185) 7,482 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances<	•	14.997	5,240
Research and development net income (455,201) (225,064) Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables 26,711 101,437 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances<		· ·	·
Share-based expense 1,380,492 - Operating loss before working capital changes (1,698,050) (645,269) Changes in working capital: (Increase) / decrease in other receivables (26,185) 7,482 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development grant received 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning o	_		
Changes in working capital: (1ncrease) / decrease in other receivables (26,185) 7,482 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Patents and trademarks expenditure (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Share-based expense	· · · · · · · · · · · · · · · · · · ·	-
(Increase) / decrease in other receivables (26,185) 7,482 Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities 20,662,919 (109,560) Patents and trademarks expenditure (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Operating loss before working capital changes	(1,698,050)	(645,269)
Increase in trade and other payables 26,711 101,437 Increase in provisions 70,605 - Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities Value of the control of t	Changes in working capital:		
Net cash used in operating activities (1,626,919) (536,350)	(Increase) / decrease in other receivables	(26,185)	7,482
Net cash used in operating activities (1,626,919) (536,350) Cash flows from investing activities (150,562) (109,560) Patents and trademarks expenditure (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Increase in trade and other payables	26,711	101,437
Cash flows from investing activities (150,562) (109,560) Patents and trademarks expenditure (201,698) (237,521) Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Increase in provisions		
Patents and trademarks expenditure (150,562) (109,560) Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance of ordinary shares 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Net cash used in operating activities	(1,626,919)	(536,350)
Research and development expenditure (201,698) (237,521) Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	Cash flows from investing activities		
Research and development rebate 493,195 225,064 Research and development grant received 37,134 237,671 Purchase of plant & equipment (47,279) (110,844) Net cash generated from investing activities 130,790 4,810 Cash flows from financing activities 590,000 528,000 Share issuance of ordinary shares 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	·	· · · · · · · · · · · · · · · · · · ·	` '
Research and development grant received Purchase of plant & equipment Net cash generated from investing activities37,134 (47,279)237,671 (110,844)Cash flows from financing activities130,7904,810Cash flows from financing activities590,000528,000Share issuance of ordinary shares590,000528,000Share issuance cost-(99,659)Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789	·	, ,	, ,
Purchase of plant & equipment(47,279)(110,844)Net cash generated from investing activities130,7904,810Cash flows from financing activities590,000528,000Issuance of ordinary shares590,000528,000Share issuance cost-(99,659)Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789	·	•	
Net cash generated from investing activities130,7904,810Cash flows from financing activities590,000528,000Issuance of ordinary shares590,000528,000Share issuance cost-(99,659)Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789	, e		•
Cash flows from financing activities Issuance of ordinary shares 590,000 528,000 Share issuance cost - (99,659) Net cash generated from financing activities 590,000 428,341 Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789	·		
Issuance of ordinary shares590,000528,000Share issuance cost-(99,659)Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789	Net cash generated from investing activities	130,790	4,810
Share issuance cost-(99,659)Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789			
Net cash generated from financing activities590,000428,341Net decrease in bank balances(906,129)(103,199)Bank balances at beginning of half-year3,818,763509,789	•	590,000	•
Net decrease in bank balances (906,129) (103,199) Bank balances at beginning of half-year 3,818,763 509,789			
Bank balances at beginning of half-year 3,818,763 509,789	Net cash generated from financing activities	590,000	428,341
	Net decrease in bank balances	(906,129)	(103,199)
Bank balances at end of half-year 2,912,634 406,590	Bank balances at beginning of half-year	3,818,763	509,789
	Bank balances at end of half-year	2,912,634	406,590

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

These notes form an integral part of and should be read in conjunction with the accompanying financial report:

1. GENERAL INFORMATION

Nature of Operations

The principal activities of the Group during the course of the half-year were research and development activities applied to the Company's world leading solar glass technology.

Basis of Preparation and Statement of Compliance

These general purpose consolidated interim financial statements have been prepared in accordance with the requirements of the Corporations Act 2001 and AASB 134 'Interim Financial Reporting'. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

They do not include all of the information required in an annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the Annual Report of the Group for the year ended 30 June 2018 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Securities Exchange Listing Rules and Corporations Act 2001.

The consolidated interim financial report has been approved and authorised for issue, in accordance with a resolution of Directors, on the 28 February 2019.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or Amended Accounting Standards and Interpretations Adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

AASB 9 Financial Instruments

AASB 9 Financial Instruments replaces AASB 139's 'Financial Instruments: Recognition and Measurement' requirements. It makes major changes to the previous guidance on the classification and measurement of financial assets and introduces an 'expected credit loss' model for impairment of financial assets.

When adopting AASB 9, the Group elected not to restate prior periods. Rather, differences arising from the adoption of AASB 9 in relation to classification, measurement, and impairment are recognised in opening retained earnings as at 1 July 2018.

Based on its assessment, the Group does not believe that the new classification requirements will have a material impact on its accounting for trade and other receivables that are managed on a fair value basis. As at 31 December 2018, the Group had no receivables that are managed on a fair value basis.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

AASB 15 Revenue from Contracts with Customers

AASB 15 replaces AASB 118 Revenue, AASB 111 Construction Contracts and several revenue-related Interpretations. The new Standard has been applied as at 1 July 2018 using the modified retrospective approach. Under this method, the cumulative effect of initial application is recognised as an adjustment to the opening balance of retained earnings at 1 July 2018 and comparatives are not restated. In accordance with the transition guidance, AASB 15 has only been applied to contracts that are incomplete as at 1 July 2018. Based on its assessment, the Group does not believe that the new requirements will have a material impact on its accounting for revenue.

3. SEGMENT INFORMATION

Management has determined the operating segments based on reports reviewed by the Board of Directors for making strategic decisions. The current Board of Directors monitors the business based on operational and geographic factors and have determined that there is only one relevant business segment being Clearvue Technologies Limited. The Group is domiciled in Australia and all revenue and expenditure is generated from Australia, and all assets are located in Australia.

4. RESTATEMENT OF COMPARATIVES

During the half-year ended 31 December 2018 review, it was agreed to restate prior deferred development costs, project revenue and costs associated with the Greenhouse project year (as stated below). The restatement is to ensure that the relevant project revenue and costs are treated appropriately according to AASB 120 Government Grants and Disclosure of Government Assistance. Extracts (being only those line items affected) are disclosed below.

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Extract)

	Consolidated 31 Dec 2017 Reported \$	Adjustment \$	Consolidated 31 Dec 2017 Restated \$
Other income	181,655	225,064	406,719
Total revenue	238,000	225,064	463,064
Loss before income tax	(673,624)	225,064	(448,560)
Loss for the year, representing total comprehensive loss of the half-year	(673,624)	225,064	(448,560)
Basic loss per share Diluted loss per share	Cents (1.06) (1.06)	Cents (0.53) (0.53)	Cents (1.59) (1.59)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

4. RESTATEMENT OF COMPARATIVES (CONTINUED)

Consolidated Statement of Financial Position (Extract)

	Consolidated 30 Jun 2018 Reported \$	Adjustment \$	Consolidated 30 Jun 2018 Restated \$
Other receivables	99,791	18,797	118,588
Total current assets	3,918,554	18,787	3,937,351
Intangible assets Total non-current assets	1,756,196 1,864,572	(263,037) (263,037)	1,493,159 1,601,535
Total assets	5,783,126	(244,240)	5,538,886
Net assets	5,466,174	(244,240)	5,221,934
Retained earnings	(7,369,663) 5,466,174	(244,240)	(7,613,903)
Total equity	5,466,174	(244,240)	5,221,934

Consolidated Statement of Cash Flows (Extract)

	Consolidated 31 Dec 2017 Reported \$	Adjustment \$	Consolidated 31 Dec 2017 Restated \$
Loss before income tax	(673,624)	225,064	(448,560)
Adjustment for: Research and development net income	-	(225,064)	(225,064)
Research and development expenditure	-	(237,521)	(237,521)
Research and development rebate	225,214	(150)	225,064
Research and development grant received	-	237,671	237,671

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

4. RESTATEMENT OF COMPARATIVES (CONTINUED)

Notes to the Consolidated Financial Statements (Extract)

	Consolidated 30 Jun 2018 Reported \$	Adjustment \$	Consolidated 30 Jun 2018 Restated \$
Trade and other receivables Grants receivable Total	99,791	18,797 18,797	18,797 118,588
Intangible assets Research and development Total	844,057 1,756,196	(263,037) (263,037)	581,020_ 1,493,159

5. OTHER INCOME

	Consolidated 31 Dec 2018	Consolidated 31 Dec 2017 Restated \$
Rebates and refunds	683,195	225,064
Government grant	-	181,326
Interest received	6,107	329
Other	2,000	
	691,302	406,719

6. ADMINISTRATIVE EXPENSES

	Consolidated 31 Dec 2018 \$	Consolidated 31 Dec 2017 \$
		·
Consulting fees	250,251	134,727
General expense	276,086	77,609
Legal fees	7,145	14,372
Listing fees	59,553	99,428
Materials and supplies	345,507	3,339
Salary and wages	407,716	93,300
Share-based payments expense	1,380,492	-
Superannuation	31,076	8,436
Travel, accommodation and conference	325,666	69,379
	3,083,492	500,590

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

7.	CASH AND CASH EQUIVALENTS	Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 \$
	Cash and cash equivalents	2,912,634	3,818,763
	Bank balances are denominated in Australian dollars.		
8.	TRADE AND OTHER RECEIVABLES	Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 Restated \$
	Trade receivables R&D rebate receivable Grants receivable Goods and service tax (GST) Term deposits Prepayments	2,200 190,000 18,347 56,042 55,354 12,390 334,333	18,797 95,738 - 4,053 118,588
9.	PLANT AND EQUIPMENT	Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 \$
	Plant and equipment	140,658	108,376
	Movements for the half-year Cost: Balance at 1 July 2018 Additions Balance at 31 December 2018		\$ 127,967 47,279 175,246
	Accumulated depreciation: Balance at 1 July 2018 Depreciation for the period Balance at 31 December 2018		19,591 14,997 34,588
	Carrying amount: Balance at 31 December 2018		140,658

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

10.	INTANGIBLE ASSETS		0
		Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 Restated \$
	Patents and trademarks Research and development	1,036,803 581,020 1,617,823	912,139 581,020 1,493,159
	Movements in patents and trademarks for the half-year		\$
	Cost: Balance at 1 July 2018 Additions		1,101,955 154,080
	Balance at 31 December 2018		1,256,035
	Accumulated amortisation: Balance at 1 July 2018 Amortisation for the period Balance at 31 December 2018		189,816 29,416 219,232
	Carrying amount:		
	Balance at 31 December 2018		1,036,803
	Movements in research and development for the half-year Cost:	ar	
	Balance at 1 July 2018 - Restated Balance at 31 December 2018		581,020 581,020
11.	TRADE AND OTHER PAYABLES		
		Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 \$
	Trade payables	368,776	287,203
	Other payables Amount withheld from salary and wages Accruals	25,445 15,884 66	16,064 11,315 2,370
	•	410,171	316,952
12.	PROVISIONS		
		Consolidated 31 Dec 2018 \$	Consolidated 30 Jun 2018 \$
	<u>Current</u> Leave provisions	65,600	· -
	Non-Current Leave provisions	5,005	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

13.

SHARE CAPITAL	31 Dec 2018 NO. OF SHARES	30 Jun 2018 NO. OF SHARES	31 Dec 2018 \$	<u>30 Jun 2018</u> \$
Ordinary shares – fully paid	97,380,300	95,020,300	10,583,302	9,993,302
			NO. OF SHARES	\$
Movements in share capital Balance at 1 July 2018 Options exercised during palance at 31 December 2	period ¹		95,020,300 2,360,000 97,380,300	9,993,302 590,000 10,583,302

¹ On the 21 September 2018, 1,860,000 unlisted options were exercised at an exercise price of \$0.25 per option. Subsequently, on the 5 October 2018, 500,000 unlisted options were exercised at an exercise price of \$0.25 per option.

The share capital of the Company consists only of fully paid ordinary shares, the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting of the Company. The balance includes 39,026,956 fully paid ordinary shares that are held in escrow for 24 months from the date of official quotation.

14. SHARE-BASED PAYMENTS RESERVE

	31 Dec 2018 \$	30 Jun 2018 \$
Share plan for Directors *	536,900	536,900
Options issued to Lead Manager Offer	225,635	225,635
Options issued to Consultants	1,380,492	-
Performance shares to Directors	2,080,000	2,080,000
	4,223,027	2,842,535

^{*} The share plan arises on the grant of loan for a term of 10 years to Directors and related parties for the purchase of the Company's ordinary shares under the Clearvue Loan Funded Share Plan in 2017. Amounts are transferred out of the reserve and into share capital when the loans are settled.

	NO. OF OPTIONS	\$
Movement in Share-Based Payments Reserve		
Balance at 1 July 2018	56,958,024	2,842,535
Options exercised during the half-year	(2,360,000)	-
Options issued to Consultants ¹	8,550,000	1,380,492
Balance at 31 December 2018	63,148,024	4,223,027

¹ On the 21 December 2018, 8,550,000 unlisted options exercisable at \$0.25 per option were issued to consultants of the Company for services provided. The options are exercisable at \$0.25 each with an expiry date of 21 June 2021. All the options vested on grant date. The Black Scholes option pricing model was used to value these options and inputs used are as stated in the table below.

Grant Date	Expiry Date	Exercise Price	Share Price	Volatility	Risk Free Rate
21 Dec 2018	21 Jun 2021	\$0.25	\$0.28	96.65%	1.97%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

15. EVENTS ARISING SINCE THE END OF THE REPORTING PERIOD

On 31 January 2019, Ms Deborah Ho was appointed as joint company secretary.

On 1 February 2019, 350,000 fully paid ordinary shares were issued at nil consideration to an employee pursuant to the Company's Employee Share Plan.

On 27 February 2019, the Company executed a Distribution Licence Agreement with Grafsol General Trading LLC.

No other matter or circumstances, not otherwise dealt with in this report have arisen since the end of the financial year to the date of this report which has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or state of affairs of the Group in subsequent financial years.

16. CONTINGENT ASSETS & LIABILITIES

There were no contingent assets or liabilities as at 31 December 2018 (2017: nil).

17. COMMITMENTS

	Consolidated 31 Dec 2018 \$	Consolidated 31 Dec 2017 \$
Capital commitment		
Within 1 year	65,816	161,315
Within 5 years	71,609	254,835
	137,425	416,150
Operating lease commitment		
Within 1 year	45,694	-
Within 5 years	66,932	
	112,626	

Operating lease commitments includes amounts for offices, photocopier and internet services, expiring within 3 years.

18. DIVIDENDS

No dividend has been declared or paid out in the half-year ended 31 December 2018 (2017: nil). The directors do not recommend the declaration of a dividend.

DIRECTORS' DECLARATION

In the opinion of the directors of Clearvue Technologies Limited:


- (a) the consolidated financial statements and notes set out on pages 8 to 15 are in accordance with the Corporations Act 2001, including:
 - (i) complying with Accounting Standard AASB 134 Interim Financial Reporting; and
 - (ii) giving a true and fair view of its financial position as at 31 December 2018 and of their performance for the period 1 July 2018 to 31 December 2018; and
- (b) at the date of this declaration, there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

The declaration is made in accordance with a resolution of the Board of Directors required by section 303(5)(a) of the Corporations Act 2001.

Victor Rosenberg

Perth WA,

Date: 28 February 2019



Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000

Correspondence to: PO Box 7757 Cloisters Square Perth WA 6850

T +61 9480 2000 F +61 9480 2000 E info.wa@au.gt.com W www.grantthornton.com.au

Independent Auditor's Review Report

To the Members of ClearVue Technologies Limited

Report on the review of the half year financial report

Conclusion

We have reviewed the accompanying half year financial report of ClearVue Technologies Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2018, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, nothing has come to our attention that causes us to believe that the half year financial report of ClearVue Technologies Limited does not give a true and fair view of the financial position of the Group as at 31 December 2018, and of its financial performance and its cash flows for the half year ended on that date, in accordance with the *Corporations Act 2001*, including complying with Accounting Standard AASB 134 *Interim Financial Reporting*.

Directors' responsibility for the half year financial report

The Directors of the Company are responsible for the preparation of the half year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2018 and its performance for the half year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of ClearVue Technologies Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389 www.grantthornton.com.au

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.



A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

GRANT THORNTON AUDIT PTY LTD

Chartered Accountants

L A Stella

Partner - Audit & Assurance

Perth, 28 February 2019